Displaying 61 - 80 of 1505
FTC Proposes Amendments to Strengthen and Modernize the Health Breach Notification Rule
Ovulation Tracking App Premom Will be Barred from Sharing Health Data for Advertising Under Proposed FTC Order
FTC Deepens Inquiry into Prescription Drug Middlemen
Amgen Inc. and Horizon Therapeutics plc, FTC v.
FTC Sues to Block Biopharmaceutical Giant Amgen from Acquisition That Would Entrench Monopoly Drugs Used to Treat Two Serious Illnesses
FTC Releases Agenda for May 18 Workshop on Proposed Changes to the Eyeglass Rule
FTC Sues to Stop the Potentially Illegal Integration of New Orleans Area Hospitals Over Failure to Follow Federal Reporting Law
FTC Sends 37 New Cease and Desist Letters Regarding Agency’s Eyeglass Rule
FTC Approves Final Order against The Bountiful Company in First Case Alleging Hijacking of Online Product Reviews
The Bountiful Company
In February 2023, the FTC took action against a marketer of vitamins and other supplements called The Bountiful Company for abusing a feature of Amazon.com to deceive consumers into thinking that its newly introduced supplements had more product ratings and reviews, higher average ratings, and “#1 Best Seller” and “Amazon’s Choice” badges. The case against Bountiful marks the FTC’s first law enforcement challenging “review hijacking,” in which a marketer steals or repurposes reviews of another product. The company agreed to pay $600,000 in consumer redress to settle the FTC’s complaint. In March 2024, the Commission announced it was sending more than $527,000 to impacted consumers.
Public Workshop Examining Proposed Changes to the Ophthalmic Practice Rules (Eyeglass Rule)
FTC to Host Public Workshop on Proposed Changes to Its Ophthalmic Practice Rules, also Known as the Eyeglass Rule, in May in Washington, DC
Dalal A. Akoury d/b/a AWAREmed, et al., U.S. v.
In March 2023, the FTC took action under the Opioid Addiction Recovery Fraud Prevention Act, suing Dr. Dalal A. Akoury and a set of companies she controls that operate as AWAREmed Health & Wellness Resource Center, a medical clinic, for making a wide range of false or unsupported claims for addiction treatment services, cancer treatment services, and the treatment of other serious conditions. The proposed order settling the Commission’s complaint bars Dr. Akoury and her AWAREmed clinic from making such unsupported claims and requires her to pay a $100,000 civil penalty.
FTC Approves Final Order against LCA-Vision, Halting Alleged Bait-and-Switch Advertising for LASIK Laser Eye Surgery
LCA-Vision Inc. d/b/a LasikPlus
In January 2023, the FTC issued an order requiring Ohio-based LCA-Vision, doing business as LasikPlus and Joffe MediCenter, to pay $1.25 million for using deceptive bait-and-switch advertising to trick consumers into believing they could have their vision corrected for less than $300. The order also bans the defendants from making the misrepresentations detailed in the complaint. The Commission approved the final consent order in March 2023.
BetterHelp, Inc.; Analysis of Proposed Consent Order To Aid Public Comment
Statement of Commissioner Alvaro M. Bedoya Joined by Commissioner Rebecca Kelly Slaughter Regarding Amazon.com, Inc.'s Acquisition of 1Life Healthcare, Inc.
Displaying 61 - 80 of 1505